SCHEMBL5145012

SCHEMBL5145012

O=C1NC(=O)C(=C(Cc2ccccc2F)c2ccc(-c3cc(C(=O)O)ccc3Cl)o2)N1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.42
POLB P06746 3/20 0.42
KMT2A Q03164 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
PKM P14618 3/20 0.39
KDM4E B2RXH2 2/20 0.39
S1PR4 O95977 2/20 0.39
MAPT P10636 2/20 0.38
ALDH1A1 P00352 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RECQL P46063 1/20 0.38
STAT3 P40763 1/20 0.36
MAPK1 P28482 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
SENP1 Q9P0U3 1/20 0.35
TDP2 O95551 1/20 0.35
SLC1A3 P43003 1/20 0.35
ERCC5 P28715 1/20 0.34
FEN1 P39748 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5147466 0.87 MEN1 (0.44) MEN1POLBKMT2AL3MBTL1TDP1
SCHEMBL5147463 0.87 MEN1 (0.44) MEN1POLBKMT2AL3MBTL1TDP1
SCHEMBL5145398 0.71 ENPP2 (0.43) MEN1POLBKMT2AL3MBTL1TDP1
SCHEMBL5146594 0.70 ALDH1A1 (0.55) MEN1POLBKMT2AL3MBTL1TDP1
SCHEMBL5145004 0.68 TDP1 (0.75) MEN1POLBKMT2AL3MBTL1TDP1
SCHEMBL5145007 0.68 TDP1 (0.75) MEN1POLBKMT2AL3MBTL1TDP1
SCHEMBL14426477 0.67 KMT2A (0.68) MEN1POLBKMT2AL3MBTL1TDP1
SCHEMBL5145205 0.66 PPM1G (0.45) MEN1POLBKMT2AL3MBTL1TDP1
SCHEMBL5143420 0.63 PIM1 (0.46) MEN1POLBKMT2AL3MBTL1TDP1
SCHEMBL14363094 0.61 L3MBTL1 (0.50) MEN1POLBKMT2AL3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718308-A4 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORP (CA) 2007-07-18 EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 EP disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 US disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 MEN1 4004/4885POLB 2945/4885KMT2A 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.